Dernières nouvelles pour Charles River (NYSE:CRL) Stock

Charles River

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Charles River Laboratories International, Inc. Common Stock

Charles River Laboratories International Inc

Cresco Labs Inc

CORCEL EXPL INC by CORCEL EXPL INC

CARDINAL ENERGY LTD ORD by Cardinal Energy Ltd.

Cardinal Energy Ltd

CIRCUIT RESEARCH LABS INC by Circuit Research Labs, Inc.

CENTRAL PRKNG F/T 5.25PFD by Central Parking Finance Trust

Central Parking Financial Trust

Cerillion PLC

News

Charles River Labs And CHDI Foundation Announce Extension Of Ongoing Drug Discovery Partnership Into Foreseeable Future

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Wolfe Research analyst Andrew Rosivach upgraded the rating for Newmark Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRK#NASDAQ">NMRK</a>) from Peer Perform to Outperform. Newmark Group shares closed at $10.46 on Thursday. <a href="https://www.benzinga.com/quote/nmrk/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Redburn Atlantic analyst Jamie Clark upgraded Charles River Laboratories International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) from Neutral to Buy but lowered the price target from $188 to $182. Charles River shares closed at $135.60 on Thursday. <a href="https://www.benzinga.com/quote/crl/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Tami Zakaria upgraded the rating for Waste Management, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) from Neutral to Overweight and raised the price target from $225 to $277. Waste Management shares closed at $233.32 on Thursday. <a href="https://www.benzinga.com/quote/wm/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Gabe Hajde upgraded Sonoco Products Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SON#NYSE">SON</a>) from Underweight to Overweight and raised the price target from $45 to $55. Sonoco Prods shares closed at $45.11 on Thursday. <a href="https://www.benzinga.com/quote/son/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Alexander Goldfarb upgraded the rating for The Macerich Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAC#NYSE">MAC</a>) from Underweight to Neutral and maintained the price target of $16. Macerich shares closed at $15.22 on Thursday. <a href="https://www.benzinga.com/quote/mac/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying WM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="581" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/23112439/image-308-1024x581.png" alt="" class="wp-image-926277" style="width:653px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/23112439/image-308-1024x581.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/23112439/image-308-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/23112439/image-308-768x435.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/23112439/image-308.png 1141w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45585296/jim-cramer-says-medical-properties-trust-has-too-much-risk-likes-this-industrial-stock"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45585296/jim-cramer-says-medical-properties-trust-has-too-much-risk-likes-this-industrial-stock">Jim Cramer Says Medical Properties Trust Has &#8216;Too Much Risk,&#8217; Likes This Industrial Stock</a> </li>
</ul>
Photo via Shutterstock

Upgrades

Analyst Ratings

Trading Ideas

NMRK

This Waste Management Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Redburn Atlantic analyst Jamie Clark upgrades Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) from Neutral to Buy and lowers the price target from $188 to $182.

Price Target

Redburn Atlantic Upgrades Charles River to Buy, Lowers Price Target to $182

10 analysts have shared their evaluations of Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $160.4, a high estimate of $175.00, and a low estimate of $140.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 3.72%. 
<img src="https://www.benzinga.com/files/images/story/2025/1746730834_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Charles River among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$155.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$140.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$145.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$155.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$170.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$175.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Casey Woodring</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$165.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$173.00</td>
<td>$177.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$160.00</td>
<td>$166.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$166.00</td>
<td>$205.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Charles River. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Charles River compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Charles River's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Charles River's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CRL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Charles River analyst ratings.</a>
<h2>About Charles River</h2>
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model &amp; services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery &amp; safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
<h3>Charles River: Financial Performance Dissected</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Charles River's revenue growth over a period of 3M has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -1.08%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Charles River's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -21.52%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Charles River's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -5.96%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Charles River's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -2.78%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.79.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 10 Analyst Ratings Have To Say About Charles River

Barclays analyst Luke Sergott maintains Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) with a Equal-Weight and raises the price target from $145 to $155.

Barclays Maintains Equal-Weight on Charles River, Raises Price Target to $155

Baird analyst Eric Coldwell maintains Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) with a Neutral and raises the price target from $118 to $140.

Baird Maintains Neutral on Charles River, Raises Price Target to $140

Charles River Laboratories International Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) stock is trading higher on Wednesday after the company released better than expected <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45248168/charles-river-laboratories-announces-first-quarter-2025-results" rel="noreferrer noopener">first-quarter 2025 earnings</a>.
The life science tools company reported:
<ul>
<li>Revenue of $984.2 million, a decrease of 2.7% year over year, beating the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of $941.97 million</a>.</li>
<li>Operating margin decreased to 7.6% from 12.5% in the first quarter of 2024, primarily due to lower revenue and higher amortization expense related to the accelerated amortization of certain CDMO client relationships.</li>
<li>On an adjusted basis, the first-quarter operating margin increased to 19.1% from 18.5%, driven primarily by the benefit of cost savings resulting from restructuring initiatives, partially offset by lower revenue.</li>
<li>Adjusted EPS of $2.34, up from $2.27 a year ago, surpassing the consensus estimate of $2.08.</li>
<li>Revenue for the Research Models and Services (RMS) segment was $213.1 million, a decrease of 3.5% year over year.</li>
<li>The impact of foreign currency translation reduced revenue by 1.0%.</li>
<li>Organic revenue decreased by 2.5%, due primarily to the timing of NHP shipments in China and lower revenue for the Cell Solutions business. The decline was partially offset by higher sales of small research models across all geographic areas, principally driven by higher pricing.</li>
<li>Revenue for the Discovery and Safety Assessment (DSA) segment was $592.6 million, down 2.1%.</li>
<li>The impact of foreign currency translation reduced DSA revenue by 0.6%, and the divestiture of a small DSA site reduced reported revenue by 0.1%.</li>
<li>Organic revenue decreased by 1.4%, driven primarily by lower revenue for discovery services.</li>
<li>Manufacturing Solutions&#8217; revenue reached $178.5 million, down 3.6%.</li>
<li>The impact of foreign currency translation reduced Manufacturing revenue by 1.4%.</li>
<li>Organic revenue decreased 2.2%, primarily driven by the CDMO and Biologics Testing businesses. This was partially offset by higher revenue in the Microbial Solutions business.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/04/44764201/whats-going-on-with-charles-river-certara-simulations-plus-stocks-on-friday" rel="noreferrer noopener">What&#8217;s Going On With Charles River, Certara, Simulations Plus Stocks On Friday?</a>
Charles River CEO James Foster cited a an improvement in DSA booking activity &#8220;to the highest level in two years.&#8221; 
Guidance: Charles River raised its 2025 outlook to reflect improved net bookings in the DSA segment during the first quarter, which are expected to result in incremental DSA revenue this year, particularly during the first half.
The company expects 2025 revenue to decline between 5.5% and 3.5% compared to the prior range of 7% and 4.5% on a reported basis and organically at 4.5% and 2.5% <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43832606/analyst-sees-charles-river-as-preclinical-leader-but-maintains-neutral-stance" rel="noreferrer noopener">(5.5% and 3.5% prior)</a>.
Charles River raised its fiscal year 2025 adjusted EPS guidance from $9.10-$9.60 to $9.30–$9.80 versus a consensus of $9.33.
The company also released several governance updates, including appointing four new directors to its board, reaching a cooperation agreement with Elliott Investment Management, and initiating a strategic review to enhance <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45248128/charles-river-laboratories-announces-governance-updates-and-strategic-review-to-enhance-long-term-" rel="noreferrer noopener">long-term shareholder value</a>.
Price Action: CRL stock is up 22.9% at $141.83 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45252907/uber-sees-strong-trip-growth-but-warns-on-us-rideshare-pressure-in-2025-outlook" target="_blank" rel="noreferrer noopener">Uber Sees Strong Trip Growth But Warns About US Rideshare Pressure In 2025 Outlook</a></li>
</ul>

Earnings

Guidance

Health Care

Movers

General

Charles River Laboratories' Q1 Earnings Beat Consensus, Stock Trades Higher On Signs Of Demand Stabilization

U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Wednesday.
Shares of Rockwell Automation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) rose sharply during Wednesday's session after the company reported better-than-expected second-quarter financial results and raised its FY25 adjusted EPS and GAAP EPS guidance. Also, the company issued FY25 sales guidance <a href="https://www.benzinga.com/quote/ROK/earnings">above estimates</a>.
Sales fell 6% year over year (Y/Y) and slid 4% organically to $2.001 billion, versus the consensus of $1.96 billion. Total ARR grew 8% Y/Y. Adjusted EPS was $2.45 (-2% Y/Y), above the analyst consensus of $2.09.
Rockwell Automation shares jumped 12.4% to $284.30 on Wednesday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul>
<li>Porch Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCH#NASDAQ">PRCH</a>) shares jumped 46% to $9.28 following a first-quarter revenue and EPS beat. Additionally, the company raised its FY25 sales guidance above estimates.</li>
<li>NerdWallet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRDS#NASDAQ">NRDS</a>) gained 29.7% to $10.98 following a first-quarter revenue beat and after the company issued second-quarter revenue guidance above estimates.</li>
<li>Angi Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGI#NASDAQ">ANGI</a>) gained 29% to $14.47 after the company reported better-than-expected quarterly financial results.</li>
<li>Opendoor Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPEN#NASDAQ">OPEN</a>) gained 29% to $0.9049 after the company reported first-quarter financial results and beat its adjusted EPS and revenue estimates.</li>
<li>Oscar Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSCR#NYSE">OSCR</a>) shares jumped 28.8% to $16.84 after the company reported better-than-expected first-quarter financial results and issued FY25 sales guidance above estimates.</li>
<li>Opendoor Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPEN#NASDAQ">OPEN</a>) rose 27% to $0.8966 after the company reported first-quarter financial results and beat its adjusted EPS and revenue estimates.</li>
<li>The ODP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODP#NASDAQ">ODP</a>) gained 23.6% to $16.83 after the company reported better-than-expected first-quarter financial results.</li>
<li>Eos Energy Enterprises, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) gained 23.3% to $6.28 after the company reported better-than-expected quarterly financial results.</li>
<li>Rigel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) gained 23.1% to $22.48 after the company reported upbeat quarterly financial results.</li>
<li>Charles River Laboratories International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) shares rose 21.6% to $140.38 after the company reported better-than-expected quarterly financial results and raised its FY25 guidance.</li>
<li>Elanco Animal Health Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NASDAQ">ELAN</a>) gained 16.5% to $11.09 after the company reported better-than-expected first-quarter financial results and raised its FY25 revenue guidance above estimates. Also, the company issued FY25 adjusted EPS guidance with its midpoint above estimates.</li>
<li>Resideo Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REZI#NYSE">REZI</a>) shares rose 14.2% to $19.94 after the company reported better-than-expected second-quarter financial results and issued FY25 guidance above estimates.</li>
<li>ZEEKR Intelligent Technology Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZK#NYSE">ZK</a>) gained 10.5% to $24.97.</li>
<li>Gen Digital Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEN#NASDAQ">GEN</a>) gained 10% to $28.31 after the company reported better-than-expected fourth-quarter financial results and issued FY26 guidance above estimates.</li>
<li>The Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) shares rose 9.3% to $100.81 after the company reported better-than-expected quarterly results.</li>
<li>Voya Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOYA#NYSE">VOYA</a>) gained 8.2% to $65.22 after the company reported better-than-expected first-quarter financial results.</li>
<li>Grand Canyon Education, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOPE#NASDAQ">LOPE</a>) rose 7% to $198.49 following upbeat quarterly earnings.</li>
<li>BorgWarner Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWA#NYSE">BWA</a>) gained 4.5% to $30.32 following better-than-expected quarterly earnings.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45251088/top-3-financial-stocks-that-may-plunge-in-may">Top 3 Financial Stocks That May Plunge In May</a> </li>
</ul>
Photo via Shutterstock

Intraday Update

Markets

ANGI

ELAN

EOSE

LOPE

NRDS

OPEN

OSCR

PRCH

REZI

RIGL

VOYA

Rockwell Automation Posts Better-Than-Expected Earnings, Joins Oscar Health, Charles River Laboratories, Walt Disney, Voya Financial And Other Big Stocks Moving Higher On Wednesday

WIIM

Charles River shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 guidance.

<h3>Gainers</h3>
<ul>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares increased by 88.9% to $2.57 during Wednesday's pre-market session. The market value of their outstanding shares is at $7.1 million. </li>
<li>ZyVersa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) stock moved upwards by 45.13% to $0.8. The company's market cap stands at $2.8 million. </li>
<li>Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) shares moved upwards by 21.56% to $140.3. The company's market cap stands at $7.1 billion. As per the press release, Q1 earnings came out today. </li>
<li>Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) shares rose 21.09% to $22.11. The market value of their outstanding shares is at $389.4 million. The company's, Q1 earnings came out yesterday. </li>
<li>Kazia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>) stock rose 19.56% to $3.85. The market value of their outstanding shares is at $21.5 million. </li>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares moved upwards by 17.68% to $0.56. The company's market cap stands at $6.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock decreased by 55.0% to $0.08 during Wednesday's pre-market session. The company's market cap stands at $1.9 million. </li>
<li>Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) stock decreased by 24.35% to $5.5. The company's market cap stands at $506.9 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>AquaBounty Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQB#NASDAQ">AQB</a>) stock decreased by 20.22% to $0.75. The company's market cap stands at $2.9 million. </li>
<li>Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) stock declined by 18.08% to $38.3. The company's market cap stands at $3.7 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Geron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) stock decreased by 14.41% to $1.13. The market value of their outstanding shares is at $719.6 million. As per the press release, Q1 earnings came out today. </li>
<li>Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) shares fell 12.54% to $91.7. The company's market cap stands at $6.2 billion. The company's, Q1 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GERN

KZIA

LNTH

MYGN

SRPT

TOVX

ZVSA

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

<ul>
<li>The board has approved the appointment of four new directors.</li>
<li>A special board committee will lead a full review of the company's business strategy and how it manages its capital.</li>
<li>The company has reached a cooperation agreement with Elliott Investment Management.</li>
</ul>

Charles River Laboratories Announces Board Changes and Strategic Review

Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) raises FY2025 GAAP EPS guidance from $4.30-$4.80 to $4.35-$4.85 vs $5.68 analyst estimate..

Charles River Raises FY2025 GAAP EPS Guidance from $4.30-$4.80 to $4.35-$4.85 vs $5.68 Est

Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) raises FY2025 Adj EPS guidance from $9.10-$9.60 to $9.30-$9.80 vs $9.33 analyst estimate. Raises FY2025 sales outlook from $3.77 billion-$3.87 billion to $3.83 billion-$3.91 billion vs $3.82 billion estimate.

Charles River Raises FY2025 Adj EPS Guidance from $9.10-$9.60 to $9.30-$9.80 vs $9.33 Est; Raises FY2025 Sales Guidance from $3.77B-$3.87B to $3.83B-$3.91B vs $3.82B Est

Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) reported quarterly earnings of $2.34 per share which beat the analyst consensus estimate of $2.08 by 12.5 percent. This is a 3.08 percent increase over earnings of $2.27 per share from the same period last year. The company reported quarterly sales of $984.17 million which beat the analyst consensus estimate of $941.97 million by 4.48 percent. This is a 2.75 percent decrease over sales of $1.01 billion the same period last year.

Earnings Beats

Charles River Q1 Adj. EPS $2.34 Beats $2.08 Estimate, Sales $984.17M Beat $941.97M Estimate

ACAD

ACDC

ACRE

ACVA

ADMA

ADNT

ADTN

AIRG

ALNT

ALTG

ALTO

ALVO

AMPH

AMPL

AMRK

AMRN

AOSL

APLS

ARIS

ARMN

ASLE

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AVDX

AXON

AXTA

AZTA

BAND

BBDO

BBGI

BBSI

BGSF

Brighthouse Financial, Inc. - Common Stock

BLBD

BLMN

BLZE

BMBL

BRKR

BROS

BTMD

BXSL

BYND

CAPL

CCSI

CDLX

CENT

CENTA

CENX

CEVA

CIVI

CMTG

CNDT

COHR

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRNC

CRNT

CSGS

CSTE

CTVA

CVNA

CYRX

Earnings Scheduled For May 7, 2025

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/09/25</td>
<td>$42.00</td>
<td>$31.6K</td>
<td>1.4K</td>
<td>3.6K</td>
</tr>
<tr>
<td>ALDX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$2.50</td>
<td>$62.2K</td>
<td>973</td>
<td>2.0K</td>
</tr>
<tr>
<td>MDT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/23/25</td>
<td>$83.00</td>
<td>$187.0K</td>
<td>24</td>
<td>1.0K</td>
</tr>
<tr>
<td>KNSA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$20.00</td>
<td>$42.7K</td>
<td>308</td>
<td>299</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$80.00</td>
<td>$41.0K</td>
<td>5.0K</td>
<td>286</td>
</tr>
<tr>
<td>ALT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$6.00</td>
<td>$30.0K</td>
<td>5.1K</td>
<td>200</td>
</tr>
<tr>
<td>INSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$72.50</td>
<td>$31.9K</td>
<td>2.7K</td>
<td>197</td>
</tr>
<tr>
<td>PFE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$30.00</td>
<td>$77.4K</td>
<td>29.7K</td>
<td>115</td>
</tr>
<tr>
<td>CRL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$115.00</td>
<td>$27.1K</td>
<td>434</td>
<td>104</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$480.00</td>
<td>$50.9K</td>
<td>849</td>
<td>63</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a call option sweep that happens to be bullish, expiring in 4 day(s) on May 9, 2025. This event was a transfer of 80 contract(s) at a $42.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $31.6K, with a price of $395.0 per contract. There were 1486 open contracts at this strike prior to today, and today 3666 contract(s) were bought and sold. 
• For ALDX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALDX#NASDAQ">ALDX</a>), we notice a call option trade that happens to be bullish, expiring in 11 day(s) on May 16, 2025. This event was a transfer of 1778 contract(s) at a $2.50 strike. The total cost received by the writing party (or parties) was $62.2K, with a price of $35.0 per contract. There were 973 open contracts at this strike prior to today, and today 2028 contract(s) were bought and sold. 
• Regarding MDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), we observe a put option sweep with bearish sentiment. It expires in 18 day(s) on May 23, 2025. Parties traded 1000 contract(s) at a $83.00 strike. This particular put needed to be split into 28 different trades to become filled. The total cost received by the writing party (or parties) was $187.0K, with a price of $187.0 per contract. There were 24 open contracts at this strike prior to today, and today 1006 contract(s) were bought and sold. 
• Regarding KNSA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNSA#NASDAQ">KNSA</a>), we observe a call option sweep with bullish sentiment. It expires in 74 day(s) on July 18, 2025. Parties traded 50 contract(s) at a $20.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $42.7K, with a price of $855.0 per contract. There were 308 open contracts at this strike prior to today, and today 299 contract(s) were bought and sold. 
• For MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we notice a call option sweep that happens to be bullish, expiring in 46 day(s) on June 20, 2025. This event was a transfer of 79 contract(s) at a $80.00 strike. This particular call needed to be split into 23 different trades to become filled. The total cost received by the writing party (or parties) was $41.0K, with a price of $520.0 per contract. There were 5034 open contracts at this strike prior to today, and today 286 contract(s) were bought and sold. 
• For ALT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), we notice a call option trade that happens to be bearish, expiring in 137 day(s) on September 19, 2025. This event was a transfer of 200 contract(s) at a $6.00 strike. The total cost received by the writing party (or parties) was $30.0K, with a price of $150.0 per contract. There were 5132 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• For INSM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>), we notice a call option sweep that happens to be neutral, expiring in 46 day(s) on June 20, 2025. This event was a transfer of 49 contract(s) at a $72.50 strike. This particular call needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $31.9K, with a price of $658.0 per contract. There were 2748 open contracts at this strike prior to today, and today 197 contract(s) were bought and sold. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a put option sweep with bullish sentiment. It expires in 256 day(s) on January 16, 2026. Parties traded 113 contract(s) at a $30.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $77.4K, with a price of $686.0 per contract. There were 29726 open contracts at this strike prior to today, and today 115 contract(s) were bought and sold. 
• For CRL (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>), we notice a call option trade that happens to be bullish, expiring in 11 day(s) on May 16, 2025. This event was a transfer of 28 contract(s) at a $115.00 strike. The total cost received by the writing party (or parties) was $27.1K, with a price of $970.0 per contract. There were 434 open contracts at this strike prior to today, and today 104 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a put option sweep with bearish sentiment. It expires in 11 day(s) on May 16, 2025. Parties traded 7 contract(s) at a $480.00 strike. This particular put needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $50.9K, with a price of $7280.0 per contract. There were 849 open contracts at this strike prior to today, and today 63 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ALDX

Hims & Hers Health, Inc. Class A Common Stock

HIMS

INSM

KNSA

10 Health Care Stocks Whale Activity In Today's Session

The U.S. stock market staged a stunning one-month rebound, fully erasing the losses triggered by Donald Trump&#8216;s <a href="https://www.benzinga.com/topic/donald-trump">April 2 tariff announcements.</a>
From its April low of 4,835 points, the S&amp;P 500—tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)—has surged 17.5%, logging nine consecutive sessions of gains through Friday, the longest winning streak since May 2024.
Still, the rally has been far from uniform across sectors.
The sectoral rebound since April has been powerful, but only a handful of sectors have managed to fully recover to or exceed their April 2 levels, before Trump&#8217;s tariff announcements triggered a broad selloff.
Technology led the charge, surging 25.9% since the April low and now stands 3.8% above its April 2 level, the strongest full recovery among all major sectors.
Industrials and Utilities also climbed 1.8% and 1% above their early-April levels, respectively.
Sectors like Consumer Discretionary , Communication Services, Financials, Consumer Staples, and Real Estate posted strong double-digit rebounds off April lows—ranging from 8.3% to 18.9%— finally reaching April 2 levels without breaching them.
On the other end of the spectrum, Energy remains 13.4% below its April 2 level, making it the worst laggard. Health Care is still down 4% from early April, even after recovering 7.2%. Materials also underperformed, ending the period 1.9% below its pre-tariff announcement level.
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Sector</th>
<th>%chg since April lows</th>
<th>May 2 vs. April 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Communication Services Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>16.1%</td>
<td>unchanged</td>
</tr>
<tr>
<td>Consumer Staples&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>8.3%</td>
<td>unchanged</td>
</tr>
<tr>
<td>Consumer Discretionary&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>16.9%</td>
<td>unchanged</td>
</tr>
<tr>
<td>Energy&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>11.3%</td>
<td>-13.4%</td>
</tr>
<tr>
<td>Financial Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>18.9%</td>
<td>unchanged</td>
</tr>
<tr>
<td>Health Care&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>7.2%</td>
<td>-4%</td>
</tr>
<tr>
<td>Industrials&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>20.4%</td>
<td>up by 1.8%</td>
</tr>
<tr>
<td>Materials&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>16.4%</td>
<td>-1.9%</td>
</tr>
<tr>
<td>Real Estate&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>17.2%</td>
<td>unchanged</td>
</tr>
<tr>
<td>Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>25.9%</td>
<td>up by 3.8%</td>
</tr>
<tr>
<td>Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>12.2%</td>
<td>up by 1%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">Top Performing S&amp;P 500 Stocks Since April 2</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>Sector</td>
<td>Return</td>
</tr>
<tr>
<td>Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>)</td>
<td>Information Technology</td>
<td>41.22%</td>
</tr>
<tr>
<td>Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>)</td>
<td>Communication Services</td>
<td>23.45</td>
</tr>
<tr>
<td>Quanta Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>)</td>
<td>Industrials</td>
<td>23.16</td>
</tr>
<tr>
<td>GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>)</td>
<td>Industrials</td>
<td>20.78</td>
</tr>
<tr>
<td>CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>)</td>
<td>Information Technology</td>
<td>18.92</td>
</tr>
<tr>
<td>Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)</td>
<td>Information Technology</td>
<td>18.87</td>
</tr>
<tr>
<td>ServiceNow, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NASDAQ">NOW</a>)</td>
<td>Information Technology</td>
<td>18.80</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Worst Performer Since April 2</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>Sector</td>
<td>Return</td>
</tr>
<tr>
<td>Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>)</td>
<td>Information Technology</td>
<td>-26.66%</td>
</tr>
<tr>
<td>Becton, Dickinson and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>)</td>
<td>Health Care</td>
<td>-25.89</td>
</tr>
<tr>
<td>UnitedHealth Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</td>
<td>Health Care</td>
<td>-23.76</td>
</tr>
<tr>
<td>APA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>)</td>
<td>Energy</td>
<td>-21.40</td>
</tr>
<tr>
<td>Global Payments Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>)</td>
<td>Financials</td>
<td>-20.95</td>
</tr>
<tr>
<td>Targa Resources Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRGP#NYSE">TRGP</a>)</td>
<td>Energy</td>
<td>-20.79</td>
</tr>
<tr>
<td>Charles River Laboratories International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>)</td>
<td>Health Care</td>
<td>-20.00</td>
</tr>
</tbody>
</table>
</figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/25/05/45174409/nasdaq-100-leveraged-etf-tqqq-surges-55-as-tech-rally-jobs-data-boost-risk-appetite">Nasdaq-100 Leveraged ETF TQQQ Surges 5.5% As Tech Rally, Jobs Data Boost Risk Appetite</a></li>
</ul>
Photo: Shutterstock

Equities

AVGO

CRWD

ENPH

NFLX

PLTR

TRGP

XLRE

Select Sector SPDR-Consumer Discretionary

Wall Street Roars Back From April Tariff Sell-Off: Which Sectors Are Still Underwater?

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$105.00</td>
<td>$35.3K</td>
<td>866</td>
<td align="right">366</td>
</tr>
<tr>
<td>THC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$115.00</td>
<td>$60.0K</td>
<td>332</td>
<td align="right">193</td>
</tr>
<tr>
<td>VSTM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$6.00</td>
<td>$25.6K</td>
<td>5.2K</td>
<td align="right">152</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$445.00</td>
<td>$119.4K</td>
<td>1</td>
<td align="right">98</td>
</tr>
<tr>
<td>PTCT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$49.00</td>
<td>$55.5K</td>
<td>2</td>
<td align="right">67</td>
</tr>
<tr>
<td>SYK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$390.00</td>
<td>$27.3K</td>
<td>137</td>
<td align="right">46</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$135.00</td>
<td>$27.2K</td>
<td>1.7K</td>
<td align="right">26</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$700.00</td>
<td>$76.8K</td>
<td>53</td>
<td align="right">10</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$530.00</td>
<td>$41.0K</td>
<td>119</td>
<td align="right">9</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding CRL (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>), we observe a call option sweep with bearish sentiment. It expires in 24 day(s) on May 16, 2025. Parties traded 58 contract(s) at a $105.00 strike. This particular call needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $35.3K, with a price of $610.0 per contract. There were 866 open contracts at this strike prior to today, and today 366 contract(s) were bought and sold. 
• Regarding THC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>), we observe a put option sweep with neutral sentiment. It expires in 24 day(s) on May 16, 2025. Parties traded 70 contract(s) at a $115.00 strike. This particular put needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $60.0K, with a price of $860.0 per contract. There were 332 open contracts at this strike prior to today, and today 193 contract(s) were bought and sold. 
• Regarding VSTM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>), we observe a call option trade with neutral sentiment. It expires in 59 day(s) on June 20, 2025. Parties traded 151 contract(s) at a $6.00 strike. The total cost received by the writing party (or parties) was $25.6K, with a price of $170.0 per contract. There were 5217 open contracts at this strike prior to today, and today 152 contract(s) were bought and sold. 
• Regarding ISRG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>), we observe a call option trade with bearish sentiment. It expires in 87 day(s) on July 18, 2025. Parties traded 20 contract(s) at a $445.00 strike. The total cost received by the writing party (or parties) was $119.4K, with a price of $5972.0 per contract. There were 1 open contracts at this strike prior to today, and today 98 contract(s) were bought and sold. 
• For PTCT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>), we notice a call option sweep that happens to be bearish, expiring in 241 day(s) on December 19, 2025. This event was a transfer of 50 contract(s) at a $49.00 strike. This particular call needed to be split into 22 different trades to become filled. The total cost received by the writing party (or parties) was $55.5K, with a price of $1110.0 per contract. There were 2 open contracts at this strike prior to today, and today 67 contract(s) were bought and sold. 
• For SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we notice a call option sweep that happens to be bearish, expiring in 150 day(s) on September 19, 2025. This event was a transfer of 30 contract(s) at a $390.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $27.3K, with a price of $910.0 per contract. There were 137 open contracts at this strike prior to today, and today 46 contract(s) were bought and sold. 
• For JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we notice a call option sweep that happens to be bearish, expiring in 59 day(s) on June 20, 2025. This event was a transfer of 12 contract(s) at a $135.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $27.2K, with a price of $2270.0 per contract. There were 1737 open contracts at this strike prior to today, and today 26 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option trade that happens to be bullish, expiring in 115 day(s) on August 15, 2025. This event was a transfer of 5 contract(s) at a $700.00 strike. The total cost received by the writing party (or parties) was $76.8K, with a price of $15360.0 per contract. There were 53 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
• Regarding TMO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), we observe a put option trade with bearish sentiment. It expires in 150 day(s) on September 19, 2025. Parties traded 4 contract(s) at a $530.00 strike. The total cost received by the writing party (or parties) was $41.0K, with a price of $10250.0 per contract. There were 119 open contracts at this strike prior to today, and today 9 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ISRG

PTCT

VSTM

9 Health Care Stocks With Whale Alerts In Today's Session

Wall Street pared early morning gains by midday Monday, as investor caution returned despite a temporary easing in U.S.-China trade tensions. While the initial market reaction was positive, especially in tech, enthusiasm faded as <a href="https://www.benzinga.com/markets">the trading session progressed.</a>
Over the weekend, the White House announced a provisional exemption for smartphones and semiconductors from China&#8217;s proposed 145% trade tariff. These items will instead face a 20% levy—linked to fentanyl-related enforcement—until sector-specific duties are finalized.
The development triggered a strong premarket rally in technology stocks. Yet, those gains were sharply trimmed by midday amid broader geopolitical and policy concerns.
During a White House meeting with El Salvador President Nayib Bukele, President Donald Trump said he plans to impose tariffs on pharmaceutical imports to boost domestic manufacturing. 
He reiterated a hardline stance on Iran, warning of severe consequences if Tehran develops nuclear weapons, but also suggested &#8220;flexibility&#8221; in tariff negotiations, emphasizing a desire not to harm U.S. businesses.
Defensive and domestic-oriented sectors such as real estate, utilities, and consumer staples outperformed broader markets. In contrast, consumer discretionary was the only sector trading in negative territory.
Treasury yields dropped significantly, reflecting increased demand for U.S. government debt and easing fears of foreign liquidation. The 2-year yield fell 10 basis points to 3.87%, while 10-year benchmark yield dropped 7 basis points to 4.42%.
Gold pulled back 1% to $3,200 per ounce, pausing after a three-session rally. Crude oil fell 0.8% to $61 per barrel, while natural gas slid 2.9% to $3.39 per MMBtu, eyeing its lowest level since last Wednesday.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) was little changed at $84,000, while Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) gained 2.1% to $1,630.
<h3 class="wp-block-heading">Monday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg %</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>40,326.49</td>
<td>0.3%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,377.08</td>
<td>0.3%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>18,695.41</td>
<td>0.0%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,856.16</td>
<td colspan="2">-0.2%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:30 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) inched 0.5% up to $537.23.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.4% to $403.81.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) edged 0.4% higher to $454.38.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) inched 0.1% higher to 184.74.</li>
<li>The&nbsp;Real Estate&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>) outperformed, up 1.9%; the&nbsp;Consumer Discretionary&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) lagged, down 0.5%.</li>
</ul>
In company news, Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) reported stronger-than-expected earnings during the first quarter, and shares rose 1.9%.
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Top 5 Gainers On Monday</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company </th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sandisk Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDK#NASDAQ">SNDK</a>)</td>
<td>6.91%</td>
</tr>
<tr>
<td>Charles River Laboratories Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>)</td>
<td>5.98%</td>
</tr>
<tr>
<td>Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>)</td>
<td>4.69%</td>
</tr>
<tr>
<td>First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>)</td>
<td>4.64%</td>
</tr>
<tr>
<td>Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>)</td>
<td>4.15%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Worst 5 Losers On Monday</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>)</td>
<td>-3.80%</td>
</tr>
<tr>
<td>DaVita Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>)</td>
<td>-3.61%</td>
</tr>
<tr>
<td>UnitedHealth Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</td>
<td>-3.04%</td>
</tr>
<tr>
<td>Southwest Airlines Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>)</td>
<td>-2.39%</td>
</tr>
<tr>
<td>Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</td>
<td>-2.36%</td>
</tr>
</tbody>
</table>
</figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/04/44794083/7-chipmaker-stocks-set-to-gain-as-trump-delays-tariff-blow-on-key-china-tech-imports-bank-of-america">7 Chipmaker Stocks Set To Gain As Trump Delays Tariff Blow On Key China Tech Imports: Bank Of America</a></li>
</ul>
Photo: Shutterstock

Government

Large Cap

Macro Economic Events

Regulations

Sector ETFs

Broad U.S. Equity ETFs

Econ #s

Economics

Tech

ETFs

$BTC

$ETH

AMZN

SPDR Dow Jones Industrial Average ETF Trust

FSLR

SNDK

Wall Street Pulls Back After Early Gains As Tariff Uncertainties Persist: What's Driving Markets Monday?

The U.S. Food and Drug Administration (FDA) announced its plans to end the mandatory animal testing of new drugs, a move that sent AI-enabled biotech companies such as Recursion Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) and Ginkgo Bioworks Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNA#NYSE">DNA</a>) rallying last week. 
What Happened: On Thursday, the new FDA commissioner, Martin Makary, announced a major reform to its drug evaluation standards. As per <a href="https://www.fda.gov/news-events/press-announcements/fda-announces-plan-phase-out-animal-testing-requirement-monoclonal-antibodies-and-other-drugs">the</a> agency&#8217;s press release, mandatory animal testing is no longer required for monoclonal antibody therapies and other drugs, and it would instead be replaced with &#8220;more effective, human relevant methods.&#8221;
The agency lays out several approaches to replace animal testing, such as AI-based computational models of toxicity, cell lines, and organoid toxicity testing in a laboratory setting. 
See More: <a href="https://benzinga.com/general/biotech/25/04/44751934/fda-grants-complete-approval-to-bayers-drug-for-certain-type-cancer-with-mutation">FDA Grants Complete Approval To Bayer&#8217;s Drug For Certain Type Cancer With Mutation</a>
Calling it a &#8220;win-win for public health and ethics,&#8221; commissioner Makary adds that drug manufacturers have performed animal testing of drugs longer than was necessary, especially those &#8220;drugs that have data in broad human use internationally.&#8221;
The move sent Nvidia Corp.-backed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) Recursion Pharmaceuticals, along with Ginkgo Bioworks, Absci Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) and Schrodinger Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDGR#NASDAQ">SDGR</a>), all techBio or AI-enabled biotech companies, rallying 27.72%, 11.23%, 23%, and 27.42%, respectively, following the announcement. 
On the flip side, however, companies operating in the preclinical laboratory services industry, such as Charles River Laboratories Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) and Inotiv Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOTV#NASDAQ">NOTV</a>) witnessed a steep pullback of nearly 28%, and 44%, respectively, being major legacy players in the contract research organization (CRO) space.
Why It Matters: Leading biotech analysts have, however, expressed mixed views on the FDA&#8217;s announcement, with Leerink Partners analysts referring to it as &#8220;more public relations than a change in policy,&#8221; adding that they expect minimal near-term impact on preclinical testing, as <a href="https://www.biospace.com/fda/fda-to-replace-some-animal-testing-with-ai-human-organoid-lab-models">reported</a> by BioSpace.
Analyst Rick Weissenstein of TD Cowen had a rather optimistic take on the announcement, <a href="https://www.axios.com/2025/04/10/fda-animal-testing-drug-trials">stating</a> to Axios that the initiative &#8220;combines deregulatory themes and cutting-edge technology,&#8221; in service of a broadly popular goal of reducing animal testing.
Weissenstein further adds that the FDA&#8217;s plans could help accelerate drug development with the use of AI and by leveraging computational models, resulting in lower costs and improved safety. 
<figure class="wp-block-image aligncenter size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="148" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/14043638/Screenshot-2025-04-14-at-2.05.54-PM-1024x148.png" alt="" class="wp-image-869611" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/14043638/Screenshot-2025-04-14-at-2.05.54-PM-1024x148.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/14043638/Screenshot-2025-04-14-at-2.05.54-PM-300x44.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/14043638/Screenshot-2025-04-14-at-2.05.54-PM-768x111.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/14043638/Screenshot-2025-04-14-at-2.05.54-PM-1536x223.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/14043638/Screenshot-2025-04-14-at-2.05.54-PM.png 1600w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Despite its rally over the past week, shares of Recursion Pharmaceuticals don&#8217;t score too well on Benzinga&#8217;s Edge Stock Rankings, but what about Ginkgo Bioworks and Schrodinger? Sign up for <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Benzinga Edge Stock Rankings</a> today for more such insights.
Read More: <a href="https://benzinga.com/insights/options/25/03/44203832/this-is-what-whales-are-betting-on-recursion-pharmaceuticals">This Is What Whales Are Betting On Recursion Pharmaceuticals</a>
Photo courtesy: Shutterstock

Biotech

ABSI

NOTV

NVDA

RXRX

SDGR

Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing

Press Releases

Charles River Laboratories to Present at Barclays Global Healthcare Conference

Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform

Charles River Laboratories Schedules First-Quarter 2025 Earnings Release and Conference Call

Charles River Leverages Advanced Technology to Expedite Oncology Drug Discovery and Development

Charles River Announces Inaugural Advanced Therapy Incubator Program Cohort

Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value

Charles River Laboratories Announces First-Quarter 2025 Results

Charles River Laboratories to Present at Bank of America Health Care Conference

Charles River and CHDI Foundation Extend Multi-Decade Collaboration on Huntington's Disease Research

Charles River Laboratories to Present at William Blair and Jefferies Conferences

FHTX

MRNA

SANA

Comments

Charles River

Actualités

Dernières nouvelles pour Charles River (NYSE:CRL) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL